CTOs on the Move

Centre for Commercialization of Regenerative Med

www.ccrm.ca

 
Centre for Commercialization of Regenerative Medicine , a Canadian not-for-profit organization funded by the Government of Canada`s Networks of Centres of Excellence program, the Province of Ontario, and leading academic and industry partners, supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. CCRM aims to accelerate the translation of scientific discovery into marketable products for patients with specialized teams funding, and infrastructure. CCRM sources and evaluates intellectual property from around the globe, offers various consulting services, conducts development projects with partners, and establishes new companies built around strategic bundles of ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.ccrm.ca
  • The Banting Institute Suite 110-100 College Street
    Toronto, ON CAN M5G 1L5
  • Phone: 416.978.3751

Executives

Name Title Contact Details
Kim Warren
Chief Technology Officer Profile

Similar Companies

FirstString Research Inc

FirstString Research was founded on a vision to deliver clinically relevant and effective solutions for the treatment of diseases based upon insights and understanding from the molecular and cellular contexts that define the underlying pathology.

SkylineDx

SkylineDx is a pioneer in the field of molecular diagnostics through developing and commercializing innovative, signature-based diagnostics with a high clinical value that help to provide physicians and patients with the best individual care possible. At SkylineDx we transform life sciences into the daily practice of clinical diagnostics. We enable patients to benefit sooner and safer from new insights in the molecular basis of disease. We can truly make a difference by making our love of life tangible as state-of-the-art diagnostic products with a high clinical value. Our products are designed to support clinicians in making the right choices for their patients. This provides a unique and very real difference. Obvious perhaps, but never taken for granted here at SkylineDx.

Vascular Biogenics Limited Therapeutics

VBL Therapeutics (NASDAQ: VBLT) is Phase 3 clinical biotechnology company using the machinery of the body to precisely address disease progression. The company has utilized its proprietary gene targeting and antibody platforms to create a pipeline of exquisite solutions for people with difficult to treat cancers and chronic inflammatory diseases. Our lead oncology candidate is Ofravec (VB-111), a first-in-class, targeted anti-cancer gene-therapy agent with a dual mechanism in development to target solid tumors. Ofravec is currently being studied in the OVAL international Phase 3 registration-enabling clinical trial to treat people with platinum-resistant ovarian cancer. Founded in 2000, VBL is based in Modiin, Israel and has recently opened operations in New York.

Biolex Therapeutics

Biolex Therapeutics is a Pittsboro, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Concentric Analgesics

Concentric Analgesics, Inc. is a private, biotechnology company focused on discovering and developing novel, non-opioid therapeutics for the management of acute and chronic pain.